ArticleWorld journal of surgical oncology2026
Antitumor efficacy and molecular mechanism of lenvatinib combined with vitamin K2 against hepatocellular carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Antitumor efficacy and molecular mechanism of lenvatinib combined with vitamin K2 against hepatocellular carcinoma.World journal of surgical oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to investigate the impact of lenvatinib combined with vitamin K2 on hepatocellular carcinoma (HCC) cells and to explore the underlying mechanisms.
methodsCell proliferation was assessed via the CCK-8 assay. Cell migration and invasion abilities were evaluated using Transwell assays. Protein and gene expression were analyzed by Western blot and RT-qPCR, respectively. A murine xenograft model was employed to validate the therapeutic effects.
resultsThe combination of lenvatinib and vitamin K2 more effectively inhibited the proliferation, migration, and invasion of HCC cells compared to monotherapies. Transcriptome analysis identified five commonly altered cell cycle-related genes: OSR2, ETFBKMT, FBXO32 (upregulated) and ATF5, PTPN14 (downregulated). RT-qPCR and Western blot further confirmed that the combination treatment significantly increased the expression of OSR2 and FBXO32 genes and decreased the protein level of PTPN14. Furthermore, functional studies demonstrated that knockdown of OSR2 or FBXO32 attenuated the synergistic anti-proliferative and pro-apoptotic effects of the combination therapy, while overexpression of PTPN14 antagonized this synergistic efficacy, confirming the pivotal roles of these genes in mediating the combined action. Additionally, in vivo experiments showed that the combination treatment significantly inhibited tumor growth in tumor-bearing mice, outperforming either monotherapy.
conclusionsLenvatinib combined with vitamin K2 exerts enhanced anti-tumor effects in HCC, likely by modulating key genes including OSR2, FBXO32, and PTPN14. This combination represents a promising therapeutic strategy worthy of further clinical investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.